<?xml version="1.0" ?>
<DOC>
   <DOCID>LA030294-0039</DOCID>
   <HEADLINE> NEW DRUG SEEMS TO SLOW EFFECTS OF GEHRIG ' S DISEASE</HEADLINE>
   <TEXT> An experimental new drug appears to be the first to slow the fatal progression of Lou Gehrig ' s disease , which until now has defied all attempts at treatment . The medicine , called riluzole , is not a cure.But &quot; survival almost doubled in some patients &quot; in a study financed by the manufacturer , Dr. Jeffrey Rothstein of Johns Hopkins University said . &quot; that ' s just unheard of. &quot; Rothstein is co-directing another , larger study of the treatment . The study by the manufacturer , Rhone-Poulenc Rorer , is being reported in this week ' s New England Journal of Medicine . The illness , formally known as amyotrophic_lateral_sclerosis , or ALS , killed Gehrig , a New York Yankees ' first_baseman , in 1941 . ALS is a nerve disease that robs people of muscle control , resulting in weakness and wasting . Eventually , victims lose all control of their muscles , including breathing . Whether this drug will turn_out to play a major role in the illness remains to be seen . Some experts are skeptical .</TEXT>
</DOC>
